Notice of Interim Results

RNS Number : 8846J

Oxford Biomedica PLC

23 July 2013

 

Oxford BioMedica: Notice of Interim Results

Results date: 29 August 2013

Oxford, UK - 23 July 2013: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, will be announcing its interim results for the six months ended 30 June 2013 on Thursday, 29 August 2013.

An analyst briefing will be held at 09:30am GMT on Thursday, 29 August 2013 at the offices of M:Communications, 11^th Floor, CityPoint, 1 Ropemaker Street, London, EC2Y 9AW.  An audio replay will be made available shortly after the presentation on the Company's website: www.oxfordbiomedica.co.uk.

-Ends-

For further information, please contact:
Oxford BioMedica plc: Lara Mott, Head of Investor Relations and Corporate Communications	Tel: [phone]
Media Enquiries: Mary-Jane Elliott/Matthew Neal M:Communications	Tel: [phone]

Notes to editors

1. About Oxford BioMedica^®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector^® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

 

END

 

 

NORDLLFLXDFBBBX